PepGen reports Q3 net loss of $18.6M; cash $195.8M; Phase 1 PGN-EDO51 data positive

PepGen Inc.

2022-Q3 EPS reported -$4.18

Net loss widened to $18.6M (vs $8.1M in Q3 2021); R&D expenses $16.0M; G&A $3.6M.
Cash and equivalents $195.8M as of Sep 30, 2022; ~23.6M shares outstanding.
Phase 1 HNV trial of PGN-EDO51 met primary endpoint; highest exon skipping vs competitors.
PGN-EDO51 Phase 2a in DMD patients and PGN-EDODM1 Phase 1/2 both expected H1 2023.
Appointed Habib Dable (former Acceleron CEO) to Board; pipeline milestones by year-end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PepGen Inc. reported the third quarter ended September 30, 2022 results: net income Net loss was $18.6 million for the three months ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Net income: Net loss was $18.6 million for the three months ended September 30, 2022
Result: reported results

Exact text from the filing

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the third quarter ended September 30, 2022

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

PepGen Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-024184

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.